Lymphocyte Subsets in Defense Against New Pathogens in Patients with Cancer

Arango-Prado, Maria del Carmen; Valverde, Carlos Agustín Villegas; Torres-López, Griselda; Soto-Pardeiro, Pilar; Suárez-Reyes, Anamary; Faxas-García, María E.; Diéguez-Rodríguez, Vivian; Gracia, Elías; Esperón-Noa, Roberto; Castillo-Bahi, Ramón del; Méndez-Rosabal, Ariadna; Curbelo-Alfonso, Luis

doi:10.37757/mr2022.v24.n2.5

MEDICC Review

2022

DOI: 10.37757/mr2022.v24.n2.5

|View full text |Cite

Lymphocyte Subsets in Defense Against New Pathogens in Patients with Cancer

Maria del Carmen Arango-Prado

Carlos Agustín Villegas Valverde

Griselda Torres-López

et al.

Abstract: How to citeComplete issue More information about this article Journal's webpage in redalyc.org Scientific Information System Redalyc Network of Scientific Journals from Latin America and the Caribbean, Spain and Portugal Project academic non-profit, developed under the open access initiative MEDICC Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Peripheral Blood Lymphocyte Subsets and Long-Term Clinical Outcomes in Prostate Cancer Patients: An Eight- Year Follow-up Study

Chen,

Hao,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: The clinical outcomes of prostate cancer (PC) may be influenced by changes in immune profiles. However, the precise correlation between the long-term prognosis of PC and circulating lymphocytes remains uncertain. Therefore, our study aimed to characterize circulating lymphocyte subsets and investigate their relationship with the long-term clinical outcomes in PC patients. Materials: The prospective cohort study included patients with a pathological diagnosis of PC and Gleason Grades ranging from 5 to 10. Lymphocyte counts were assessed in peripheral blood using flow cytometry. The prognostic value of various lymphocytes was analyzed in the entire cohort, with survival curves generated using the Kaplan-Meier method and multivariate analysis performed using Cox regression models. Results: Between January 2001 and June 2021, a total of 94 eligible patients with prostate cancer were prospectively enrolled. The median follow-up duration for the study was 98 months. Non-survivors exhibited lower levels of CD4(+)/CD8(+) ratio, CD19(+), and CD19(+)CD5(−) B lymphocytes compared to survivors. Grouping by each cutoff point of the lymphocytes respectively, the lower level of total CD3(+) T cells, CD3(+)CD4(+) T cells, the CD4(+)/CD8(+) ratio, total CD19(+) B cells, CD19(+)CD5(+) B cells, CD19(+)CD5(-) B cells showed poor survival. Multivariate Cox regression analysis confirmed the worse prognosis associated with higher PSA (HR=2.493, 95%CI: 1.356-4.584, P=0.003), lower CD3(+)CD4(+) T lymphocytes (HR=0.379, 95%CI: 0.170-0.843, P=0.017), lower total CD19(+) B cell (HR=0.398, 95%CI:0.187-0.845, P=0.016) and higher CD3(-)CD16(+)CD56(+) NK cells(HR=2.355, 95%CI: 1.175-4.723, P=0.016). Conclusion: Our findings revealed that a reduced level of CD4(+) T lymphocytes, diminished CD19(+) B cells, and an elevated level of NK cells were associated with poor survival. This suggests potential involvement of B lymphocytes, CD4(+) T lymphocytes, and NK cells in prostate cancer, with implications for the long-term prognosis of these elderly patients.

show abstract

Peripheral Blood Lymphocyte Subsets and Long-Term Clinical Outcomes in Prostate Cancer Patients: An Eight- Year Follow-up Study

Chen,

Hao,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lymphocyte Subsets in Defense Against New Pathogens in Patients with Cancer

Cited by 1 publication

References 47 publications

Peripheral Blood Lymphocyte Subsets and Long-Term Clinical Outcomes in Prostate Cancer Patients: An Eight- Year Follow-up Study

Peripheral Blood Lymphocyte Subsets and Long-Term Clinical Outcomes in Prostate Cancer Patients: An Eight- Year Follow-up Study

Contact Info

Product

Resources

About